Diabetes Care 25:583-592, 2002
© 2002 by the American Diabetes Association, Inc.
Reviews/Commentaries/Position Statements Review |
Posttransplantation Diabetes
A systematic review of the literature
Victor M. Montori, MD, MSC1,
Ananda Basu, MD1,
Patricia J. Erwin2,
Jorge A. Velosa, MD3,4,
Sherine E. Gabriel, MD, MSC5 and
Yogish C. Kudva, MD1,4
1 Division of Endocrinology, Diabetes, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic, Rochester, Minnesota
2 Medical Library, Mayo Clinic, Rochester, Minnesota
3 Division of Nephrology and Internal Medicine, Mayo Clinic, Rochester, Minnesota
4 Transplant Center, Mayo Clinic, Rochester, Minnesota
5 Section of Clinical Epidemiology, Mayo Clinic, Rochester, Minnesota.
OBJECTIVES To systematically review the incidence of posttransplantation diabetes (PTD), risk factors for its development, prognostic implications, and optimal management.
RESEARCH DESIGN AND METHODS We searched databases (MEDLINE, EMBASE, the Cochrane Library, and others) from inception to September 2000, reviewed bibliographies in reports retrieved, contacted transplantation experts, and reviewed specialty journals. Two reviewers independently determined report inclusion (original studies, in all languages, of PTD in adults with no history of diabetes before transplantation), assessed study methods, and extracted data using a standardized form. Meta-regression was used to explain between-study differences in incidence.
RESULTS Nineteen studies with 3,611 patients were included. The 12-month cumulative incidence of PTD is lower (<10% in most studies) than it was 3 decades ago. The type of immunosuppression explained 74% of the variability in incidence (P = 0.0004). Risk factors were patient age, nonwhite ethnicity, glucocorticoid treatment for rejection, and immunosuppression with high-dose cyclosporine and tacrolimus. PTD was associated with decreased graft and patient survival in earlier studies; later studies showed improved outcomes. Randomized trials of treatment regimens have not been conducted.
CONCLUSIONS Physicians should consider modification of immunosuppressive regimens to decrease the risk of PTD in high-risk transplant recipients. Randomized trials are needed to evaluate the use of oral glucose-lowering agents in transplant recipients, paying particular attention to interactions with immunosuppressive drugs.
Abbreviations: OR, odds ratio PTD, posttransplantation diabetes RR, risk ratio

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. W. Chan, C. Y. Cheung, Y. L. Liu, Y. H. Chan, H. S. Wong, W. L. Chak, K. S. Choi, K. F. Chau, and C. S. Li
Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single centre study
Nephrol. Dial. Transplant.,
October 1, 2008;
23(10):
3337 - 3342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. J. Kuypers, K. Claes, B. Bammens, P. Evenepoel, and Y. Vanrenterghem
Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM)
Nephrol. Dial. Transplant.,
June 1, 2008;
23(6):
2033 - 2042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Delgado, J. M. Diaz, I. Silva, J. M. Osorio, A. Osuna, B. Bayes, R. Lauzurica, E. Arellano, J. M. Campistol, R. Dominguez, et al.
Unmasking Glucose Metabolism Alterations in Stable Renal Transplant Recipients: A Multicenter Study
Clin. J. Am. Soc. Nephrol.,
May 1, 2008;
3(3):
808 - 813.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Kang, M. S. Kim, Y. S. Kim, C. H. Kim, S. J. Han, S. W. Chun, K. Y. Hur, C. M. Nam, C. W. Ahn, B. S. Cha, et al.
A Polymorphism in the Zinc Transporter Gene SLC30A8 Confers Resistance Against Posttransplantation Diabetes Mellitus in Renal Allograft Recipients
Diabetes,
April 1, 2008;
57(4):
1043 - 1047.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Z. Sulemanjee, R. Merla, S. D. Lick, S. M. Aunon, M. Taylor, M. Manson, L. S.C. Czer, and E. R. Schwarz
The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2008;
13(1):
13 - 31.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Kang, M. S. Kim, Y. S. Kim, K. Y. Hur, S. J. Han, C. M. Nam, C. W. Ahn, B. S. Cha, S. I. Kim, and H. C. Lee
A Variant of the Transcription Factor 7-Like 2 (TCF7L2) Gene and the Risk of Posttransplantation Diabetes Mellitus in Renal Allograft Recipients
Diabetes Care,
January 1, 2008;
31(1):
63 - 68.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-S. Wang, S.-T. Wang, W.-J. Yao, T.-T. Chang, and P. Chou
Hepatitis C Virus Infection and the Development of Type 2 Diabetes in a Community-based Longitudinal Study
Am. J. Epidemiol.,
July 15, 2007;
166(2):
196 - 203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kamar, C. Mariat, M. Delahousse, J. Dantal, A. Al Najjar, E. Cassuto, N. Lefrancois, O. Cointault, G. Touchard, F. Villemain, et al.
Diabetes mellitus after kidney transplantation: a French multicentre observational study
Nephrol. Dial. Transplant.,
July 1, 2007;
22(7):
1986 - 1993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Hjelmesaeth, L. T. Hagen, A. Asberg, K. Midtvedt, O. Storset, C. E. Halvorsen, L. Morkrid, A. Hartmann, and T. Jenssen
The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man
Nephrol. Dial. Transplant.,
June 1, 2007;
22(6):
1743 - 1749.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Burroughs, K. L. Lentine, S. K. Takemoto, J. Swindle, G. Machnicki, K. Hardinger, D. C. Brennan, W. D. Irish, and M. A. Schnitzler
Influence of Early Posttransplantation Prednisone and Calcineurin Inhibitor Dosages on the Incidence of New-Onset Diabetes
Clin. J. Am. Soc. Nephrol.,
May 1, 2007;
2(3):
517 - 523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Y. Hur, M. S. Kim, Y. S. Kim, E. S. Kang, J. H. Nam, S. H. Kim, C. M. Nam, C. W. Ahn, B. S. Cha, S. I. Kim, et al.
Risk Factors Associated With the Onset and Progression of Posttransplantation Diabetes in Renal Allograft Recipients
Diabetes Care,
March 1, 2007;
30(3):
609 - 615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Crutchlow and R. D. Bloom
Transplant-Associated Hyperglycemia: A New Look at an Old Problem
Clin. J. Am. Soc. Nephrol.,
March 1, 2007;
2(2):
343 - 355.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Rodrigo, G. Fernandez-Fresnedo, R. Valero, J. C. Ruiz, C. Pinera, R. Palomar, J. Gonzalez-Cotorruelo, C. Gomez-Alamillo, and M. Arias
New-Onset Diabetes after Kidney Transplantation: Risk Factors
J. Am. Soc. Nephrol.,
December 1, 2006;
17(12_suppl_3):
S291 - S295.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Morales and B. Dominguez-Gil
Impact of Tacrolimus and Mycophenolate Mofetil Combination on Cardiovascular Risk Profile after Kidney Transplantation
J. Am. Soc. Nephrol.,
December 1, 2006;
17(12_suppl_3):
S296 - S303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. M. Montori, Y. G. Wang, P. Alonso-Coello, and S. Bhagra
Systematic Evaluation of the Quality of Randomized Controlled Trials in Diabetes
Diabetes Care,
August 1, 2006;
29(8):
1833 - 1838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Bamoulid, C. Courivaud, M. Deschamps, P. Mercier, C. Ferrand, A. Penfornis, P. Tiberghien, J.-M. Chalopin, P. Saas, and D. Ducloux
IL-6 Promoter Polymorphism -174 Is Associated with New-Onset Diabetes after Transplantation
J. Am. Soc. Nephrol.,
August 1, 2006;
17(8):
2333 - 2340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Stadler, C. Anderwald, T. Karer, A. Tura, T. Kastenbauer, M. Auinger, C. Bieglmayer, O. Wagner, F. Kronenberg, P. Nowotny, et al.
Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation: A sign of impaired {beta}-cell function?
Diabetes Care,
May 1, 2006;
29(5):
1031 - 1038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Hayden, P. Cote, and C. Bombardier
Evaluation of the quality of prognosis studies in systematic reviews.
Ann Intern Med,
March 21, 2006;
144(6):
427 - 437.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Armstrong, J. B. Prins, E. M. Beller, S. B. Campbell, C. M. Hawley, D. W. Johnson, and N. M. Isbel
Should an Oral Glucose Tolerance Test Be Performed Routinely in All Renal Transplant Recipients?
Clin. J. Am. Soc. Nephrol.,
January 1, 2006;
1(1):
100 - 108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Teutonico, P. F. Schena, and S. Di Paolo
Glucose Metabolism in Renal Transplant Recipients: Effect of Calcineurin Inhibitor Withdrawal and Conversion to Sirolimus
J. Am. Soc. Nephrol.,
October 1, 2005;
16(10):
3128 - 3135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. G. Radu, S. Fujimoto, E. Mukai, M. Takehiro, D. Shimono, K. Nabe, M. Shimodahira, R. Kominato, Y. Aramaki, Y. Nishi, et al.
Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity
Am J Physiol Endocrinol Metab,
February 1, 2005;
288(2):
E365 - E371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lindenfeld, R. L. Page II, R. Zolty, S. F. Shakar, M. Levi, B. Lowes, E. E. Wolfel, and G. G. Miller
Drug Therapy in the Heart Transplant Recipient: Part III: Common Medical Problems
Circulation,
January 4, 2005;
111(1):
113 - 117.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. T. Bloomgarden
Transplantation and Islet Topics
Diabetes Care,
January 1, 2005;
28(1):
213 - 219.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff
{beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes
Diabetes,
January 1, 2005;
54(1):
100 - 106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lindenfeld, G. G. Miller, S. F. Shakar, R. Zolty, B. D. Lowes, E. E. Wolfel, L. Mestroni, R. L. Page II, and J. Kobashigawa
Drug Therapy in the Heart Transplant Recipient: Part II: Immunosuppressive Drugs
Circulation,
December 21, 2004;
110(25):
3858 - 3865.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Magee and M. Pascual
Update in Renal Transplantation
Arch Intern Med,
July 12, 2004;
164(13):
1373 - 1388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S Lewis, S. L Kane-Gill, M. B. Bobek, and J. F Dasta
Intensive Insulin Therapy for Critically Ill Patients
Ann. Pharmacother.,
July 1, 2004;
38(7):
1243 - 1251.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A Davidson and A. Wilkinson
New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: An endocrinologist's view
Diabetes Care,
March 1, 2004;
27(3):
805 - 812.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. M. Cho, K. S. Park, H. S. Jung, H. J. Jeon, C. Ahn, J. Ha, S. J. Kim, B. D. Rhee, S. Y. Kim, and H. K. Lee
High Incidence of Tacrolimus-Associated Posttransplantation Diabetes in the Korean Renal Allograft Recipients According to American Diabetes Association Criteria
Diabetes Care,
April 1, 2003;
26(4):
1123 - 1128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. M. Montori, B. R. Bistrian, and M. M. McMahon
Hyperglycemia in Acutely Ill Patients
JAMA,
November 6, 2002;
288(17):
2167 - 2169.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. M. Cho, K. S. Park, H. S. Jung, Y. S. Kim, S. Y. Kim, and H. K. Lee
A Case Showing Complete Insulin Independence After Severe Diabetic Ketoacidosis Associated With Tacrolimus Treatment
Diabetes Care,
September 1, 2002;
25(9):
1664 - 1664.
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Hjelmesaeth, T. Jenssen, T. Egeland, M. Hagen, and A. Hartmann
Response to Montori et al.
Diabetes Care,
September 1, 2002;
25(9):
1667 - 1667.
[Full Text]
|
 |
|

|
 |

|
 |
 
V. M. Montori, A. Basu, P. J. Erwin, S. E. Gabriel, and Y. C. Kudva
Response to Hjelmesaeth et al.
Diabetes Care,
September 1, 2002;
25(9):
1667 - 1668.
[Full Text]
|
 |
|

|
 |

|
 |
 
C. Rigatto, P. Parfrey, V. M. Montori, A. Basu, Y. C. Kudva, C. L. Baum, A. P. McGee, A. Friedman, A. Friedman, M. Pascual, et al.
Strategies to Improve Outcomes after Renal Transplantation
N. Engl. J. Med.,
June 27, 2002;
346(26):
2089 - 2092.
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Diabetes Association.
|
|
| |
|